Literature DB >> 29460498

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population.

Chris Kay1, Jennifer A Collins1, Galen E B Wright1, Fiona Baine2,3, Zosia Miedzybrodzka4, Folefac Aminkeng1,5, Alicia J Semaka6, Cassandra McDonald1, Mark Davidson4, Steven J Madore7, Erynn S Gordon7, Norman P Gerry7, Mario Cornejo-Olivas8, Ferdinando Squitieri9, Sarah Tishkoff10, Jacquie L Greenberg2, Amanda Krause11, Michael R Hayden1.   

Abstract

Huntington disease (HD) is the most common monogenic neurodegenerative disorder in populations of European ancestry, but occurs at lower prevalence in populations of East Asian or black African descent. New mutations for HD result from CAG repeat expansions of intermediate alleles (IAs), usually of paternal origin. The differing prevalence of HD may be related to the rate of new mutations in a population, but no comparative estimates of IA frequency or the HD new mutation rate are available. In this study, we characterize IA frequency and the CAG repeat distribution in fifteen populations of diverse ethnic origin. We estimate the HD new mutation rate in a series of populations using molecular IA expansion rates. The frequency of IAs was highest in Hispanic Americans and Northern Europeans, and lowest in black Africans and East Asians. The prevalence of HD correlated with the frequency of IAs by population and with the proportion of IAs found on the HD-associated A1 haplotype. The HD new mutation rate was estimated to be highest in populations with the highest frequency of IAs. In European ancestry populations, one in 5,372 individuals from the general population and 7.1% of individuals with an expanded CAG repeat in the HD range are estimated to have a molecular new mutation. Our data suggest that the new mutation rate for HD varies substantially between populations, and that IA frequency and haplotype are closely linked to observed epidemiological differences in the prevalence of HD across major ancestry groups in different countries.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Huntington disease; genetic epidemiology; haplotypes; molecular epidemiology; trinucleotide repeat disorders

Mesh:

Substances:

Year:  2018        PMID: 29460498     DOI: 10.1002/ajmg.b.32618

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  15 in total

1.  A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.

Authors:  Chris Kay; Jennifer A Collins; Nicholas S Caron; Luciana de Andrade Agostinho; Hailey Findlay-Black; Lorenzo Casal; Dulika Sumathipala; Vajira H W Dissanayake; Mario Cornejo-Olivas; Fiona Baine; Amanda Krause; Jacquie L Greenberg; Carmen Lúcia Antão Paiva; Ferdinando Squitieri; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2019-11-07       Impact factor: 11.025

2.  Genetic Modification of Huntington Disease Acts Early in the Prediagnosis Phase.

Authors:  Jeffrey D Long; Jong-Min Lee; Elizabeth H Aylward; Tammy Gillis; Jayalakshmi Srinidhi Mysore; Kawther Abu Elneel; Michael J Chao; Jane S Paulsen; Marcy E MacDonald; James F Gusella
Journal:  Am J Hum Genet       Date:  2018-08-16       Impact factor: 11.025

3.  Common huntingtin-related genetic variation is associated with neurobiological and aging traits in humans.

Authors:  Alana N Slike; Galen E B Wright
Journal:  Cell Death Discov       Date:  2022-07-09

4.  ATXN10 Microsatellite Distribution in a Peruvian Amerindian Population.

Authors:  Diego Véliz-Otani; Miguel Inca-Martinez; Giovana B Bampi; Olimpio Ortega; Laura B Jardim; Maria Luiza Saraiva-Pereira; Pilar Mazzetti; Mario Cornejo-Olivas
Journal:  Cerebellum       Date:  2019-10       Impact factor: 3.847

5.  HTT haplogroups in Finnish patients with Huntington disease.

Authors:  Susanna Ylönen; Jussi O T Sipilä; Marja Hietala; Kari Majamaa
Journal:  Neurol Genet       Date:  2019-04-22

6.  Antagonistic pleiotropy in mice carrying a CAG repeat expansion in the range causing Huntington's disease.

Authors:  A J Morton; E A Skillings; N I Wood; Z Zheng
Journal:  Sci Rep       Date:  2019-01-10       Impact factor: 4.379

Review 7.  Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances.

Authors:  Xiaoqian Niu; Jiejian Chen; Jianqing Gao
Journal:  Asian J Pharm Sci       Date:  2018-10-22       Impact factor: 6.598

Review 8.  Distribution of the HTT Gene A1 and A2 Haplotypes Worldwide: A Systematic Review.

Authors:  Thays Andrade Apolinário; Dionatan Costa Rodrigues; Mayra Braga Lemos; Carmen Lúcia Antão Paiva; Luciana Andrade Agostinho
Journal:  Clin Med Res       Date:  2020-09-02

9.  High frequency of intermediary alleles in the HTT gene in Northern Sweden - The Swedish Huntingtin Alleles and Phenotype (SHAPE) study.

Authors:  Jimmy Sundblom; Valter Niemelä; Maria Ghazarian; Ann-Sofi Strand; Ingvar A Bergdahl; Jan-Håkan Jansson; Stefan Söderberg; Eva-Lena Stattin
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.996

10.  Parkinsonism with a Hint of Huntington's from 29 CAG Repeats in HTT.

Authors:  Sipilä Jot
Journal:  Brain Sci       Date:  2019-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.